What’s new
Colorectal cancer in the COVID-19 era
Professors David and Rachel Kerr’s proposed colorectal cancer treatment guidelines for patients during the COVID-19 era. AIMS To reduce the
Launching the 5FU Test Alliance
Today I am incredibly proud to be supporting the launch of the 5FU Test Alliance support group. They comprise a
OCB are presenting today with IBM at Pharmatec19 – London Room 7 at 11:20: Using AI Technology To Improve Outcomes For Cancer Patients
Today 25 September 2019, OCB are presenting with IBM at Pharmatec19 – London Room 7 at 11:20 – Using AI Technology
Oxford Cancer Biomarkers appoints a Medical Science Liaison Manager to strengthen operations and support continued growth
Oxford Cancer Biomarkers (OCB) have made another key appointment. The company has hired a Medical Science Liaison Manager to strengthen
Oxford Cancer Biomarkers hires two Senior Operations and Quality Control Specialists to help manage continued growth
For immediate release: 22 August 2019 Oxford Cancer Biomarkers (OCB) have hired two Senior Operations and Quality Control Specialists to
OCB appoints James Otter as new CEO
Oxford, UK, 15th July 2019: Oxford Cancer Biomarkers has appointed James Otter as Chief Executive Officer. This represents a key growth
Oxford Cancer Biomarkers Ltd. and Oxford University Hospitals offer genetic testing to prevent 5-FU/capecitabine toxicity
Oxford, 21st June 2019: Oxford University Hospitals (OUH) NHS Foundation Trust is now offering genetic testing that aims to
PRESS RELEASE: Oxford, UK and South Korea, 3rd June 2019: KwangDong Pharmaceutical Co. Ltd and Oxford Cancer Biomarkers Ltd. agree a significant investment partnership
Oxford Cancer Biomarkers (OCB) has gained a significant investment from leading South Korean healthcare company KwangDong Pharmaceutical Co. Ltd. (KDP).